Stockscreener 앱 받기
13.09
0.77%
0.10
시장 영업 전:
13.48
0.39
+2.98%
전일 마감가:
$12.99
열려 있는:
$13.09
하루 거래량:
774.68K
Relative Volume:
4.56
시가총액:
$525.35M
수익:
-
순이익/손실:
$-102.09M
주가수익비율:
-12.47
EPS:
-1.05
순현금흐름:
$-108.72M
1주 성능:
+1.43%
1개월 성능:
-8.84%
6개월 성능:
+60.81%
1년 성능:
+219.27%
1일 변동 폭
$12.96
$13.42
1주일 범위
$12.75
$13.60
52주 변동 폭
$2.74
$18.00
Dbv Technologies Adr Stock (DBVT) Company Profile
명칭
Dbv Technologies Adr
전화
33(0)155427878
주소
107 AVENUE DE LA REPUBLIQUE, CHATILLON
DBVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
13.09 | 521.34M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Guggenheim | Buy |
| 2025-05-29 | 재개 | Goldman | Sell |
| 2023-01-04 | 업그레이드 | Societe Generale | Hold → Buy |
| 2022-12-16 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-05-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-09-14 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-01-22 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2020-11-02 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-08-06 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-01-09 | 업그레이드 | Stifel | Hold → Buy |
| 2019-12-16 | 개시 | Citigroup | Buy |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 개시 | Goldman | Buy |
| 2018-12-20 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-12-20 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-10-31 | 업그레이드 | Societe Generale | Sell → Hold |
| 2017-10-24 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2017-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 개시 | Deutsche Bank | Buy |
| 2017-03-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2016-09-26 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-03 | 개시 | Barclays | Overweight |
| 2015-10-23 | 개시 | BofA/Merrill | Buy |
모두보기
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at Guggenheim - Defense World
Check Out Netskope Inc (NTSK)’s Trade Data Rather Than the Analysts’ Views - Setenews
Taking on analysts’ expectations and winning: DBV Technologies ADR (DBVT) - Setenews
DBV Technologies stock initiated with Buy rating at Guggenheim - Investing.com
DEFSEC Technologies Inc (DFSC) expanding its growth trajectory ahead - Setenews
DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
European ADRs Slip As Gains And Losses Balance Out - Finimize
US Investors Show Renewed Interest In European ADRs - Finimize
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - inkl
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - The Manila Times
DBV Technologies (NASDAQ: DBVT) marks last patient visit in 654-patient VITESSE study - Stock Titan
DBV Technologies Announces Last Patient Visit Completed in - GlobeNewswire
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Balance Sheet - Yahoo! Finance Canada
Biotech Shines As UK And European ADRs See Mixed Results - Finimize
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
DBV (NASDAQ: DBVT) to join Guggenheim Healthcare Innovation Conf.; webcast, 90-day replay - Stock Titan
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - 24matins.uk
DBV Technologies (NASDAQ: DBVT) appoints Kevin Trapp to lead Viaskin Peanut commercialization - Stock Titan
European ADRs Show Mixed Moves In Active Sectors - Finimize
DBV Technologies Appoints Dr. Philina Lee to Board - The Globe and Mail
DBV Technologies Reports Q3 2025 Financial Results - MSN
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - The Manila Times
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - The Manila Times
DBV Technologies (NASDAQ: DBVT) appoints Philina Lee to Board as independent director - Stock Titan
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - markets.businessinsider.com
Health Care And Telecom Drive European ADR Gains In The US - Finimize
European ADRs Mostly Flat As Gains And Losses Trade Off - Finimize
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
DBV Technologies (NASDAQ: DBVT) sells ~$30M in ADSs; dilution ~5.96% - Stock Titan
Dbv Technologies Adr (DBVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):